Application of polypeptide for preparing medicine for treating Alzheimer disease

A technology for Alzheimer's disease and uses, which is applied in the field of peptides used to prepare medicines for the prevention and treatment of Alzheimer's disease, and can solve problems such as memory loss, apraxia, and inability to take care of themselves in life.

Active Publication Date: 2019-04-19
XIAMEN UNIV +1
View PDF5 Cites 6 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0003] Early symptoms of AD patients include memory loss, confusion, poor concentration, aphasia, apraxia, lack of direction, etc....

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of polypeptide for preparing medicine for treating Alzheimer disease
  • Application of polypeptide for preparing medicine for treating Alzheimer disease
  • Application of polypeptide for preparing medicine for treating Alzheimer disease

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0031] Example 1: Preparation of sTREM2 41-81-Fc and sTREM2 1-171-Fc fusion proteins

[0032] Construction of pFUSE-sTREM2 1-171-hIgG1-Fc1 expression plasmid: use pFUSE-hIgG1-Fc1 (purchased from Invivogen, product number is pfuse-hg1fc1, see vector picture figure 1 ) is a eukaryotic expression vector, EcoRI and XhoI restriction sites are selected as the cloning site, and pFUSE-sTREM2 1-171-hIgG1-Fc1 expression plasmid is constructed. The steps are as follows: Design upstream primer: 5'-CG GAATTC ATGGAGCCTCTCCGGCTGC-3'SEQ ID NO: 3, where the underline is the EcoRI restriction site; downstream primer: 5'-CCG CTCGAG TTTGGGAAGGGGATTTCTC-3' SEQ ID NO: 4, where the underline is the XhoI restriction site.

[0033] The nucleotide sequence of TREM2 is (purchased from Beijing Yiqiao Sino Biotechnology Co., Ltd., article number HG11084-M: TREM-2 cDNA ORF Clone in Cloning Vector, Human):

[0034]

[0035]

[0036] The single underline is the signal peptide sequence of the prote...

Embodiment 2

[0041] Example 2: Effects of sTREM2 41-81-Fc and sTREM2 1-171-Fc fusion proteins on the inflammatory response of microglial cells

[0042] Take 5×10 5 Cell number Primary microglial cells (isolated from the brain of C57BL / 6N neonatal mice at 3-4 days after birth) were cultured in 12-well plates. After 24 hours, the cells were treated with 20nM sTREM2 41-81-Fc fusion protein, sTREM21-171-Fc fusion protein (i.e. the protein obtained in Example 1) and Fc control protein (i.e. pFUSE-hIgG1-Fc1 vector) Culture was continued for 4 hours in serum-free medium. Immediately place the cells on ice and wash 3 times with pre-cooled 1×PBS, use TRIzol reagent (Thermo Fisher, catalog number 15596018) to extract total RNA, and reverse transcription kit (Beijing Quanshijin, catalog number AT314-02) recorded as cDNA. The mRNA levels of IL-6, TNF-α, IL-1β, and β-Actin were detected by real-time quantitative PCR (RT-qPCR), and the levels of the other three inflammatory factors were analyzed usin...

Embodiment 3

[0043] Example 3 Effects of sTREM2 41-81-Fc and sTREM2 1-171-Fc fusion proteins on microglia apoptosis

[0044] to 10 5 Cell number The primary microglial cells were plated on glass slides in a 24-well plate (coated with Poly-Lysine for 24 hours in advance) for culture. After 48 hours, the cells were treated with 20nM sTREM2 41-80-Fc fusion protein, sTREM2 1-171-Fc fusion protein (i.e. protein obtained in Example 1) and Fc control protein (i.e. pFUSE-hIgG1-Fc1 vector) respectively and placed in Culture was continued for 24 hours in serum-free medium. The cells were placed on ice and washed three times with pre-cooled 1×PBS, fixed with 4% paraformaldehyde at room temperature for 20 min, and permeabilized with 0.2% Triton X-100 for 5 min. Subsequently, apoptotic cells were detected using the terminal deoxynucleotidyl transferase-mediated dUTP method for nick end labeling (TUNEL) detection kit (Promega, G3250) and nuclear staining with nuclear dye DAPI to analyze the total cell...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses application of a polypeptide for preparing medicine for treating the Alzheimer disease. The amino acid sequence is shown in SEQ ID NO:1. The polypeptide is an extracellular section 41-81 amino acids of a TREM2 receptor protein, and the nucleotide sequence is shown in SEQ ID NO:2. The polypeptide has the application that the microglial mediated inflammation reaction is promoted, apoptosis of microglial cells is restrained, the migration capability of microglial cells is enhanced, Abeta endocytosis and degradation of the microglial cells are promoted, the density of microglial cells inside a brain is increased, and Abeta amyloid plaque deposition inside the brain is lowered.

Description

technical field [0001] The invention relates to the field of biomedicine, in particular to the use of a polypeptide for preparing drugs for preventing and treating Alzheimer's disease. Background technique [0002] Alzheimer's disease (AD) is a neurodegenerative disease characterized by progressive loss of cognitive function, and is the most common type of dementia. AD is the "fourth killer" of elderly health after cardiovascular disease, cerebrovascular disease and cancer. As the global population ages, AD is becoming one of the biggest diseases of the twenty-first century. However, despite great scientific efforts, up to now, only 5 AD drugs have been approved by the US FDA and the EU EMA, all of which are only symptomatic treatments, none of which can prevent or delay the progression of AD. Therefore, finding new AD drug targets and developing targeted drugs has extremely important economic and social significance. [0003] In the early stage of AD patients, symptoms s...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K38/17A61P25/28
Inventor 陈小芬徐颖姚蕴玲
Owner XIAMEN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap